JAJu. A. Agafonova

Ju. A. Agafonova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ju. A. Agafonova has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing National Healthcare System Readiness for Value-Based Healthcare Models Implementation

    by Виталий Владимирович Омельяновский, Юлия Андреевна Агафонова, Ильдар Индусович Хайруллин, Жанна Владимировна Хайлова, Юрий Игоревич Комаров, Кирилл Игоревич Киргизов, Сергей Анатольевич Иванов, Андрей Дмитриевич Каприн

    В качестве примера для оценки готовности национальной системы здравоохранения к переходу на ценностно-ориентированные модели была рассмотрена онкологическая служба. В 2024 г. рабочая группа ведущих онкологов и специалистов в сфере организации здравоохранения провела серию совещаний по реализации проектов ценностно-ориентированного здравоохранения (ЦОЗ) в российской онкологической практике. На основании анализа международного опыта, а также результатов работы консорциума ICHOM участники пришли к единому мнению о значимости таких проектов для повышения качества медицинской помощи, учитывая восприятие пациентом процесса лечения и его исходов. Были комплексно рассмотрены критерии, предлагаемые Консорциумом ICHOM для проведения исследований в области ЦОЗ в онкологии, обсуждались ключевые параметры собираемых в ходе исследований данных, роль каждого из параметров и возможность их оценки в условиях здравоохранения в России. В ходе совещания специалисты пришли к выводу о необходимости продолжения работы в данном направлении, а также разработки единых подходов к реализации исследований ЦОЗ в онкологии в России для внедрения наилучших практик лечения пациентов. Высказаны предложения о дальнейших информационных и организационных мероприятиях, направленных на расширение знаний медицинского сообщества и пациентов о концепции ЦОЗ. Особое внимание уделено выявлению специфических организационных и методологических вызовов, характерных для российской системы здравоохранения при внедрении ценностно-ориентированного подхода в онкологии.


  • Open Access

    Endpoints and Outcomes in Real-World Oncology Clinical Trials

    by Виталий Владимирович Омельяновский, Юлия Андреевна Агафонова, Полина Алексеевна Мухортова, Филипп Васильевич Горкавенко, Юрий Игоревич Комаров, Жанна Владимировна Хайлова, Андрей Дмитриевич Каприн

    В статье акцентируется внимание на значении конечных точек как ключевого критерия надежности результатов в исследованиях реальной клинической практики (РКП), а также в клинических исследованиях в целом. Представлена актуальная классификация конечных точек (исходов) в контексте онкологических исследований, включая определения, особенности, преимущества и недостатки. Особое внимание уделено тому, как конечные точки могут быть адаптированы для использования в исследованиях РКП, чтобы обеспечить более точное и достоверное отражение клинической реальности. В практических целях перечислены виды данных (атрибутный состав), необходимых для полноценной оценки каждого из исходов. В статье речь идет о таких общепринятых для онкологических исследований конечных точках с анализом времени до наступления события, как общая выживаемость, выживаемость без прогрессирования, безрецидивная выживаемость. Также подробно рассмотрены возможности использования дополнительных и альтернативных конечных точек, таких как опухоль-специфическая выживаемость, время до неудачи или прекращения лечения и ряд других исходов.


  • Open Access

    Pharmacoeconomic study of oral anticancer therapy: results of combined ABC/VEN and frequency analysis

    by J. A. Agafonova

    Background. Modern oncology is facing a paradoxical situation in which the rapid increase in the cost of anticancer therapy is not always accompanied by a proportional improvement in its effectiveness. This creates serious economic barriers for healthcare systems worldwide. In the context of limited resources, methods for the rational allocation of the pharmaceutical budgets are becoming particularly important. The combined ABC/VEN analysis serves as an effective tool to address this challenge. This approach is especially valuable when analyzing contemporary oral anticancer drugs, which are playing an increasingly significant role in cancer treatment.Objective: To evaluate the cost structure of oral anticancer therapy using ABC/VEN and frequency analysis methods.Material and methods. Distribution by ABC categories was conducted according to generally accepted methodology. Group A (the most expensive drugs) included regimens whose total cost accounted for 80% of all expenditures. Group C (the least expensive) comprised regimens with no more than 5% of total costs. The remaining regimens formed Group B (moderately expensive), which consumed 15% of total expenditures. Final expenditures were determined based on the cost of drug therapy per regimen in a day hospital setting and the number of medical interventions provided under each regimen in 2022. The formal methodology of VEN analysis involved categorizing regimens according to the presence of drugs from the World Health Organization Model List of Essential Medicines. Separately, both ABC and VEN analyses were carried out for chemotherapy, hormone therapy, targeted therapy, and combination treatment regimens. Frequency analysis was conducted based on the number of hospitalizations of patients who received particular anticancer regimens according to real-world data from depersonalized hospitalization registry records.Results. The resource distribution analysis confirmed the Pareto principle, with 80% of financial expenditures attributed to 9.3% (95% CI 6.0–13.7) of therapeutic regimens (23 regimens) constituting the high-cost Group A. Group C (accounting for no more than 5% of expenditures) included 164 regimens (66.7%; 95% CI 60.4–72.5). The remaining drugs fell into Group B (15% of expenditures) – 24 regimens (9.8%; 95% CI 6.4–14.2). Meanwhile, 35 regimens (14.2%; 95% CI 10.1–19.2) were not used in 2022. The distribution of regimens by VEN groups was consistent with recommendations: 149 regimens (60.6%; 95% CI 54.2–66.7) for Group V, 63 regimens (25.6%; 95% CI 20.3–31.5) for Group E, and 34 regimens (13.8%; 95% CI 9.8–18.8) for Group N. The combined ABC/VEN analysis demonstrated that Group A predominantly included drugs from Group V (52.2%). However, it also revealed disproportions: a significant proportion (39.1%) of Group N drugs in Group A requires special attention and indicates the need for mechanisms to regulate the prescription of high-cost drugs.Conclusion. The findings provide a foundation for developing balanced approaches to pharmaceutical provision in oncology, combining the principles of clinical appropriateness and economic efficiency. The study justifies the need for resource allocation strategies that ensure the priority provision of evidence-based treatment regimens in the context of limited resources.


  • Open Access

    Results of adaptation of tools for standardizing value-based outcomes: analysis of ICHOM Standard Sets

    by I. I. Khayrullin, V. V. Omelyanovskiy, R. V. Gostishchev, J. A. Agafonova, N. S. Giliazetdinova, I. A. Mikhailov

    Background. Value-based healthcare (VBHC) is a model of medical care that focuses on analyzing treatment outcomes and takes into account patient-relevant results (values), clinical effectiveness, and economic costs. Although standardized assessment systems exist, such as those developed by the International Consortium for Health Outcomes Measurement (ICHOM), their practical application remains limited, slows the implementation of VBHC. The lack of unified methodologies reduces data comparability between healthcare organizations, hinders the identification of best practices, and ultimately impedes the practical realization of VBHC.Objective: To analyze and adapt standardized approaches for assessing VBHC parameters and the methodologies for their collection based on ICHOM sets.Material and methods. A comprehensive analysis was conducted on 49 ICHOM Standard Sets and 43 related publications in peer-reviewed journals. A structured study of the research objects was carried out, and potential barriers to the implementation of data collection methodologies by healthcare organizations were identified. Methods of qualitative content analysis and comparative data analysis were applied.Results. The article presents a structure of indicators for the assessment of VBHC. Particular attention is given to three key components of outcomes assessment: patient-oriented outcomes – patient-reported outcomes, clinical outcomes, and indicators of healthcare resource utilization. Standardized approaches to data collection were identified, each of which has its own limitations. Optimal monitoring timelines were determined, varying depending on the type of nosology. The results demonstrate that ICHOM standards provide a comprehensive framework for assessing value-based healthcare; however, they require adaptation to specific organizational conditions. The developed data categorization and presented conclusions provide a foundation for healthcare institutions to initiate the implementation of a value-based approach, with a focus on outcomes that matter to patients.Conclusion. The conducted analysis justifies the necessity of value-based healthcare research in accordance with the unified ICHOM Standard Sets. A unified methodology can provide a comprehensive and objective assessment of care effectiveness and foster a common understanding of the concept among all stakeholders. This approach will facilitate the transition from theory to global practice in value assessment in medicine. The next step in this direction should be the adaptation of data collection for specific sets, taking into account national characteristics and capabilities in Russia.


  • Open Access

    Development of a classification of anesthetic management methods and protocols for calculating financial costs

    by D. V. Lukyantseva, J. A. Agafonova, V. V. Omelyanovskiy, S. A. Kovaleva, D. V. Fedyaev, I. N. Pasechnik, V. V. Schukin, D. S. Blinov, A. B. Abrosimov

    Background. The costs of anesthetic support represent a significant and essential component in the expense structure of medical services, diagnosis-related groups (DRGs), and high-tech medical care (HMC) that involve anesthesia. Consequently, there is a need to develop a unified methodology for calculating such costs, which ensures transparency and objectivity in the expense structure data. Developing appropriate protocols for each anesthesia method will enable their use in future calculations when updating and forming new medical services, DRG methods, and HMC that incorporate anesthesia.Objective: to standardize approaches to calculating costs of anesthetic support.Material and methods. The study was conducted in two stages. In the first stage, a classification (list) of anesthesia methods was developed for use in calculating the financial costs of anesthetic management. In the second stage, the structural and financial detailing of protocols for anesthesia methods was carried out in accordance with the classification. At each stage, the work of specialists from the Center for Healthcare Quality Assessment and Control was validated by external experts, including anesthesiologists and intensivists.Results. The developed classification of anesthesia methods for calculating financial costs of anesthetic management, validated by external experts, included nine main methods. For each method, protocols were created for the first hour, the second, and each subsequent hour. These protocols facilitated the calculation of direct costs associated with providing anesthetic management, including labor costs for personnel directly involved in the medical service, costs of consumables, pharmaceuticals, depreciation, and indirect costs excluding the payroll of additional staff. The largest share of costs was attributed to consumables (over 50% for each anesthesia method). Additionally, calculations were made for indirect costs necessary to support the overall activities of medical organization.Conclusion. The developed protocols for each anesthesia method can be applied in future calculations when updating and forming new services and methods for DRGs and HMC that include anesthesia.


  • Open Access

    Dynamics of anticancer drug use in Russian hospitals: a five-year retrospective analysis

    by J. A. Agafonova, V. V. Omelyanovskiy

    Background. Pharmaceutical provision for oncology patients involves complex and controversial issues, particularly the use of oral anticancer drugs (ACDs) in day hospitals. These facilities often distribute oral medications for outpatient use, leading to frequent legal disputes with territorial Compulsory Health Insurance funds. To determine whether this practice changes over time, it is necessary to analyze trends in the use of ACDs.Objective: to identify trends in the use of different forms of ACDs in both inpatient and day hospital settings over a 5-year period.Material and methods. The study analyzed medical care provided in inpatient and day hospital settings using depersonalized hospitalization records from oncology-focused medical organizations. The data from 2019 to 2023 were categorized into three groups: regimens with only oral administration, including combinations of multiple oral drugs; regimens with only injectable forms, including intravenous and subcutaneous administration; and combined regimens, including oral and other forms of administration. The annual distribution and trends in the use of different forms of ACDs were analyzed for both inpatient and day hospital settings over the 5-year period. A time series analysis was carried out to assess the dynamics, including the calculation of absolute and relative growth (or decline) rates. Time series smoothing was performed using aggregation and moving average methods.Results. From 2019 to 2023, day hospitals in Russia exhibited an increase in the use of all ACD forms. The highest growth rate (79.9%) was observed for the use of oral therapy in 2020, with an overall increase from 9.25% to 29.09% over the study period. The combined regimens used in day hospitals demonstrated an increase in the proportion of oral therapy from 10.54% to 29.46%. However, inpatient settings exhibited a rise in the use of only injectable regimens from 17.65% to 23.32%. Conversely, the role of inpatient oral therapy significantly declined, with the proportion of oral-only and combined regimens decreasing from 43.59% to 1.18% and 30.47% to 12.95%, respectively.Conclusion. The results provide an evaluation of the trends in ACDs use in Russian hospitals. Despite an overall increase in the use of all ACD forms in day hospitals, oral medications exhibited the highest growth rate.

  • Open Access

    Review of Research and Key Recommendations for the Safe Use of Oral Anticancer Drugs

    by Юлия Андреевна Агафонова, Антон Владимирович Снеговой, Виталий Владимирович Омельяновский, Татьяна Сергеевна Вахрушева, Ольга Петровна Гребенникова, Владимир Юрьевич Сельчук

    Введение. Международным профессиональным сообществом созданы специализированные программы менеджмента, рекомендации и инструкции, разработанные для медицинских работников и пациентов, принимающих пероральные формы противоопухолевых лекарственных препаратов (ПОЛП). Однако в русскоязычном сегменте исследований и научной литературы имеется ограниченное количество фрагментарных данных по безопасной практике применения пероральных ПОЛП. Цель. Обозначить ключевые аспекты безопасности терапии пероральными ПОЛП, а также привести перечень рекомендаций по безопасному применению, предназначенных для использования как пациентами, так и медицинскими работниками. Авторы рекомендуют к использованию структурированные рекомендации The MASCC Oral Agent Teaching Tool (MOATT) ассоциации Multinational Association of Supportive Care in Cancer (MASCC) и адаптированные для самостоятельного применения пациентом рекомендации «Oral Chemotherapy Education» ассоциации The National Community Oncology Dispensing Association (NCODA). Авторами данной статьи осуществлен перевод и адаптация рекомендаций MASCC, которые доступны на официальном сайте ассоциации на русском языке для практического применения и проведения дальнейших исследований.

  • Changes in diagnosis-related group payment model in the Russian Federation in 2024

    by E.I. Rumyantseva, I.A. Zheleznyakova, O.S. Plakhotnik, F.S. Nikitin, T.S. Vakhrusheva, T.S. Aviaeva, A.V. Zuev, O.A. Volkova, Yu.A. Agafonova, D.V. Fedyaev, et al.

    We actualized the content and/or weight coefficients of Russian diagnosis-related groups (DRG) for inpatient and day medical care payment. Costs of medicines were calculated using actual purchase prices. Thus the weight coefficients were recalculated for several DRG including admissions for antineoplastic therapy, chronic hepatitits C treatment and treatment with the use of genetically engineered biological drugs and selective immunosupressors. Three levels of patient treatment complexity coefficients were introduced to reimburse the cost of supportive therapy in oncology. Weight coefficients for payment for radionuclide therapy were recalculated. We actualized drug therapy regimens lists covered by DRG payment. It was made for antineoplastic therapy regimens and regimens of genetically engineered drugs and selective immunosuppressors. Charges for inpatient minimally invasive operations were increased via identifying 9 new groups. Payment approaches for immunization against respiratory syncytial infection were improved. The updated grouping algorithm of cases in oncology is described.


  • Open Access

    Key aspects of medication adherence to oral anticancer drugs: A literature review

    by Ju. A. Agafonova, A. V. Snegovoy, V. V. Omelyanovskiy

    At least 25% of the anticancer drugs are intended for oral use, while the creation and rapid introduction of oral drugs into clinical practice is constantly growing. Between 2006 and 2021, 80 oral forms of anticancer drugs were approved. It has been shown that patients prefer oral therapy to intravenous therapy if such a replacement is possible with equal efficacy and toxicity of the drugs. This once again emphasizes that the issue of adherence to treatment with oral forms is open and relevant for study. Currently, adherence, as the main factor in achieving the best clinical outcome, has been studied from different perspectives. However, there are no structured data globally, and, accordingly, evidence-based and specific recommendations in the absence of adherence. The review includes data from studies performed over the past 10 years, studying the adherence of patients to treatment with oral anticancer drugs. The data sources for the review were the Medline, Embase, and Scopus databases. Literature analysis showed that the most important aspects in the field of adherence to treatment with oral anticancer drugs include the level of patient adherence to treatment, factors affecting non-compliance, correlation of treatment adherence and clinical outcomes in malignant neoplasms. At the same time, the article considers the impact of non-compliance on the health care system as a whole. The most reliable and up-to-date data in the study area were examined to subsequently identify measures aimed at achieving the best practice in the organization of healthcare for patients with malignant neoplasms. The research results demonstrate the variability and heterogeneity of data, the lack of unified methodological approaches. In turn, this prevents the formation of objective and reliable conclusions about adherence. To make rational strategic decisions on monitoring adherence to treatment, it is necessary to initiate large-scale studies, adopt uniform standard procedures and recommendations for assessing adherence.

  • Open Access

    Analysis of years of life lost due to premature cancer mortality in the Russian Federation

    by Zh. V. Khailova, A. D. Kaprin, V. V. Omelyanovsky, D. N. Pustovalov, Yu. A. Agafonova, V. O. Kusakina, S. A. Ivanov, P. V. Shegai

    Background. Burden of disease estimation allows analyses to be carried out integrally, including cause and effect assessment. the rate of life years lost due to premature mortality is part of the burden of disease analysis. given that the burden of cancer is steadily increasing, analysis of the number of years lost makes it possible to identify new strategic directions, as well as to adjust decisions already made, in the health care of cancer patients.Purpose: to estimate the loss of life expectancy as a result of premature mortality from cancer in the population of the Russian Federation.Material and Methods. the analysis was carried out using international statistical databases for disease burden estimation, databases of the Federal state statistics service (Rosstat). to determine the target groups of priority reduction of mortality from neoplasms in the Russian Federation, an estimation of the lost years of life expectancy as a result of premature mortality in the form of the e† (e-dagger) indicator was carried out. the analyzed period of the study was 2010–2019.Results. the Russian Federation is characterized by the smallest share of losses from cancer in the structure of losses from all causes of death compared to the analyzed countries (Japan, France, germany, latvia, lithuania, estonia). However, the share of losses has been intensively increasing for 10 years (in 2010 – 14.79 %, in 2019 – 17.54 %). in comparison with the analyzed countries, Russia is more characterised by losses from cancer at a younger age, with the highest value of life years lost in the age group 60–64 years. the age-standardized number of years lost in men in Russia is 67.1 % higher than in women. in the age group from 25 to 49 years of age, the loss of life expectancy due to cancer in women is higher and accounts for 0.4 years (or 19 %) of all losses, which is not typical of other age groups in which losses in men prevail. A significant regional differentiation of mortality in the constituent entities of the Russian Federation has been revealed, which is also reflected in the number of years lost.Conclusion. the potential of preventive strategies in the Russian Federation has not been fully realized – the loss of life years in young and middle age requires the correction of measures to improve preventive services and oncological care. the revealed regional differentiation allows us to identify regions with high losses for priority solutions.